Pre-emptive cytokine-induced killer (CIK) cell infusions sustain remission in high-risk leukemia patients after allogeneic stem cell transplantation.
Cytokine-induced killer (CIK) cells, mainly T cells sharing in part characteristics of natural killer (NK) cells, demonstrate non major histocompatibility complex (MHC)‐restricted cytotoxicity against hematological malignancies with negligible alloreactivity. CIK cells are licensed as an immunotherapy after allo SCT.
CIK cells may offer a curative therapeutic approach for leukemia patients whor are not eligible for specific immunotherapies.
A phase I/II clinical trial for pediatric and adult patients with hematological malignancies is in preparation.